Correlogic Systems and JEOL signed a research and development agreement focused on further enhancing the performance of mass spectrometry in a clinical setting. Correlogic and JEOL have collaborated for more than a year under an informal agreement and have made great strides in the continuing validation of various mass spectrometer-based assays, according to the companies.
“Over the past year, we have had a very close and productive research collaboration with JEOL,” said Peter J. Levine, president and CEO of Correlogic Systems. “This agreement formalizes our link.”
